affinity i-corps@nih 121014
TRANSCRIPT
![Page 1: Affinity I-Corps@NIH 121014](https://reader033.vdocuments.net/reader033/viewer/2022052700/55a202911a28ab3d268b46f7/html5/thumbnails/1.jpg)
Affinity Therapeutics
Drug delivery grafts for immediate vascular access and reduced failure rates in hemodialysis patients.
Sean T. Zuckerman, Horst von Recum, Paul Olson
1
#05
Total Interviews: 128
Weekly Average: 13
PI C Level Industry Expert
![Page 2: Affinity I-Corps@NIH 121014](https://reader033.vdocuments.net/reader033/viewer/2022052700/55a202911a28ab3d268b46f7/html5/thumbnails/2.jpg)
What we thought initially
• ~400,000 Hemodialysis pts in US
• ~80,000 pts with AV Graft
• Target is ~50% of market
2
TAM = 400,000 pts
SAM = 80,000 pts
Target = 40,000 pts Source: US Renal Data Service, 2013 Annual Report
![Page 3: Affinity I-Corps@NIH 121014](https://reader033.vdocuments.net/reader033/viewer/2022052700/55a202911a28ab3d268b46f7/html5/thumbnails/3.jpg)
What we thought initially
• Affinity’s graft would be so good we could increase market share of grafts
3
TAM = 400,000 pts
SAM = >>> 80,000 pts
Target = >>> 40,000 pts Source: US Renal Data Service, 2013 Annual Report
![Page 4: Affinity I-Corps@NIH 121014](https://reader033.vdocuments.net/reader033/viewer/2022052700/55a202911a28ab3d268b46f7/html5/thumbnails/4.jpg)
Vascular Access
• Long term vascular access critical for hemodialysis
• Arteriovenous (AV) grafts common but suboptimal option4
![Page 5: Affinity I-Corps@NIH 121014](https://reader033.vdocuments.net/reader033/viewer/2022052700/55a202911a28ab3d268b46f7/html5/thumbnails/5.jpg)
Coated AV Graft for Long Term
Vascular Access
5
BLOOD
Time
BLOOD
BLOOD
BloodBLOOD
Normal AV Graft lifespan
BLOOD BLOOD
Smooth muscle cells
AV Graft
Affinity’s coating
Affinity’s Graft lifespan
![Page 6: Affinity I-Corps@NIH 121014](https://reader033.vdocuments.net/reader033/viewer/2022052700/55a202911a28ab3d268b46f7/html5/thumbnails/6.jpg)
Steve said…
6
![Page 7: Affinity I-Corps@NIH 121014](https://reader033.vdocuments.net/reader033/viewer/2022052700/55a202911a28ab3d268b46f7/html5/thumbnails/7.jpg)
So we did…
• Interviewed 128 customers starting with
– Nephrologists
– Vascular Surgeons
– National Kidney Foundation & Kidney Disease Increasing Global Outcomes (KDIGO)
7
![Page 8: Affinity I-Corps@NIH 121014](https://reader033.vdocuments.net/reader033/viewer/2022052700/55a202911a28ab3d268b46f7/html5/thumbnails/8.jpg)
So we did…
• Interviewed 128 potential customers
– Nephrologists
– Vascular Surgeons
– National Kidney Foundation & Kidney Disease Increasing Global Outcomes (KDIGO)
– Dialysis Clinics
– More nephrologists
– Patients
8
![Page 9: Affinity I-Corps@NIH 121014](https://reader033.vdocuments.net/reader033/viewer/2022052700/55a202911a28ab3d268b46f7/html5/thumbnails/9.jpg)
Initial Canvas
9
Medical Device Co’s
Vascular Surgeons & Nephrologists
Dialysis Pts
Increase sales
Decrease stenosis rates
Ease pain & hassle
Preclinical studies
Large animal Proof of Concept studies
CROs
Value Analysis Committee
IP Licensing
Acquisition
CROs SBIR grants
Publish
Medical Device Co’s
![Page 10: Affinity I-Corps@NIH 121014](https://reader033.vdocuments.net/reader033/viewer/2022052700/55a202911a28ab3d268b46f7/html5/thumbnails/10.jpg)
Initial Canvas
10
Medical Device Co’s
Vascular Surgeons & Nephrologists
Dialysis Pts
Increase sales
Decrease stenosis rates
Ease pain & hassle
Licensing
Acquisition
Publish
![Page 11: Affinity I-Corps@NIH 121014](https://reader033.vdocuments.net/reader033/viewer/2022052700/55a202911a28ab3d268b46f7/html5/thumbnails/11.jpg)
Week 2 Canvas
11
Decision Maker @ Medical Device Co’s
Vascular Surgeons,
Nephrologists, Interventionalists
Dialysis Pts
Increase sales
Decrease stenosis rates 50%
Ease pain & hassle
Preclinical studies
Large animal Proof of Concept studies
CROs
Value Analysis Committee
IP Licensing
Acquisition
CROs SBIR grants
Publish
Medical Device Co’s
Nat’l Kidney Foundation
Center for Devices & Radiological Health
![Page 12: Affinity I-Corps@NIH 121014](https://reader033.vdocuments.net/reader033/viewer/2022052700/55a202911a28ab3d268b46f7/html5/thumbnails/12.jpg)
Customer Interviews Patient Workflow
12
Neph-rologist
Pt Vascular Surgeon
PtVascular Access
Implanted
Pt
Pt
DIALYSIS!
Pt
Interventionalist
• Nephrologist (loosely) owns the patient
• Vascular surgeons typically choose access type• Sometimes
interventionalist implants
![Page 13: Affinity I-Corps@NIH 121014](https://reader033.vdocuments.net/reader033/viewer/2022052700/55a202911a28ab3d268b46f7/html5/thumbnails/13.jpg)
Piggy-Back our MVP on MarketedGore Triple-Layered AcuSeal™
• “Sandwich” coating between layers
• Newer product = smaller market share
13
![Page 14: Affinity I-Corps@NIH 121014](https://reader033.vdocuments.net/reader033/viewer/2022052700/55a202911a28ab3d268b46f7/html5/thumbnails/14.jpg)
Week 6 Canvas
14
Decision Maker @ Medical Device Co’s
Vascular Surgeons,
Nephrologists, Interventionalists
Dialysis PtsIncrease sales
Decrease stenosis rates 50%
Ease pain & hassle
Preclinical studies
Large animal Proof of Concept studies
CROs
Value Analysis Committee
IP Licensing
Acquisition
CROs SBIR grants
Publish: JAMA, Circulation, J Vasc
Surgery,
Medical Device Co’s
Nat’l Kidney Foundation
Center for Devices & Radiological Health
Admin Contractor @ CMS
KOL
Conference: Kidney Week
Increase graft life 25%
![Page 15: Affinity I-Corps@NIH 121014](https://reader033.vdocuments.net/reader033/viewer/2022052700/55a202911a28ab3d268b46f7/html5/thumbnails/15.jpg)
Week 6 Canvas
15
Decision Maker @ Medical Device Co’s
Vascular Surgeons,
Nephrologists, Interventionalists
Dialysis PtsIncrease sales
Decrease stenosis rates 50%
Ease pain & hassle
Preclinical studies
Large animal Proof of Concept studies
CROs
Value Analysis Committee
IP Licensing
Acquisition
CROs SBIR grants
Publish: JAMA, Circulation, J Vasc
Surgery,
Medical Device Co’s
Nat’l Kidney Foundation
Center for Devices & Radiological Health
Admin Contractor @ CMS
KOL
Conference: Kidney Week
Increase graft life 25%
![Page 16: Affinity I-Corps@NIH 121014](https://reader033.vdocuments.net/reader033/viewer/2022052700/55a202911a28ab3d268b46f7/html5/thumbnails/16.jpg)
Revisited the Graft Market
• CPT Code: ~$1000 reimbursement
• $40 million Target Market
• PMA likely costs $10s of millions…
16
TAM = 400,000 pts
SAM = $80 Million
Target = $40 Million Source: US Renal Data Service, 2013 Annual Report
![Page 17: Affinity I-Corps@NIH 121014](https://reader033.vdocuments.net/reader033/viewer/2022052700/55a202911a28ab3d268b46f7/html5/thumbnails/17.jpg)
Revisited the Graft Market
• CPT Code: ~$1000 reimbursement
• $40 million Target Market
• PMA likely costs $10s of millions…
• Rethink MVP
17
TAM = 400,000 pts
SAM = $80 Million
Target = $40 Million Source: US Renal Data Service, 2013 Annual Report
![Page 18: Affinity I-Corps@NIH 121014](https://reader033.vdocuments.net/reader033/viewer/2022052700/55a202911a28ab3d268b46f7/html5/thumbnails/18.jpg)
2 Possible MVPs
18
Coated Graft
Stand alone “wrap”
FDA: Likely PMA(Predicate CDRH alone)
FDA: Likely PMA(CDRH + CDER)
![Page 19: Affinity I-Corps@NIH 121014](https://reader033.vdocuments.net/reader033/viewer/2022052700/55a202911a28ab3d268b46f7/html5/thumbnails/19.jpg)
2 Possible MVPs
19
Coated Graft
Stand alone “wrap”
FDA: Likely PMA(Predicate CDRH alone)
Existing CPT code coverage
FDA: Likely PMA(CDRH + CDER)
New HCPC code (~3 yr)
![Page 20: Affinity I-Corps@NIH 121014](https://reader033.vdocuments.net/reader033/viewer/2022052700/55a202911a28ab3d268b46f7/html5/thumbnails/20.jpg)
2 Possible MVPs
20
Coated Graft
Stand alone “wrap”
FDA: Likely PMA(Predicate CDRH alone)
Existing CPT code coverage
FDA: Likely PMA(CDRH + CDER)
New HCPC code (~3 yr)
![Page 21: Affinity I-Corps@NIH 121014](https://reader033.vdocuments.net/reader033/viewer/2022052700/55a202911a28ab3d268b46f7/html5/thumbnails/21.jpg)
Drug-eluting Wrap: Works with Fistulas or AV Grafts
21
Wrap
Adapted from Paulson WD et al. Nephrol Dial Transplant (2012);27: 1219-1224
OR Fistula
Potential wrap market is ≥ 3X AV Graft market size!
![Page 22: Affinity I-Corps@NIH 121014](https://reader033.vdocuments.net/reader033/viewer/2022052700/55a202911a28ab3d268b46f7/html5/thumbnails/22.jpg)
Design Flaw Nearly Derailed Concept
22
Wrap
Adapted from Paulson WD et al. Nephrol Dial Transplant (2012);27: 1219-1224
OR Fistula
Interview 82 = potential, “Uh Oh” moment…
![Page 23: Affinity I-Corps@NIH 121014](https://reader033.vdocuments.net/reader033/viewer/2022052700/55a202911a28ab3d268b46f7/html5/thumbnails/23.jpg)
Interview 116 (KOL) Allowed us to Detect
and Correct: Wrap Venous Tissue Only
23
![Page 24: Affinity I-Corps@NIH 121014](https://reader033.vdocuments.net/reader033/viewer/2022052700/55a202911a28ab3d268b46f7/html5/thumbnails/24.jpg)
Final Canvas
24
Decision Maker @ Medical Device Co’s
Vascular Surgeons,
Nephrologists, Interventionalists
Dialysis Pts
Increase sales
Decrease stenosis rates 50%
Ease pain & hassle
Preclinical studies
Large animal studies
CROs
Value Analysis Committee
Licensed IPLicensing
Direct Sales
CROs SBIR grants
Publish: JAMA, Circulation, J Vasc
Surgery,
Medical Device Co’s
Nat’l Kidney Foundation
Center for Devices & Radiological Health
Admin Contractor @ CMS
KOL
Conference: Kidney Week
Increase graft life 25%
Increase time to 1st
intervention 25%
Licensing
Milestone Payments
Affinity’s IP
Advisory Board
License IP
Freedom to Operate
IP costs
![Page 25: Affinity I-Corps@NIH 121014](https://reader033.vdocuments.net/reader033/viewer/2022052700/55a202911a28ab3d268b46f7/html5/thumbnails/25.jpg)
Final Canvas CS-VP
25
Decision Maker @ Medical Device Co’s
Vascular Surgeons, Nephrologists,
Interventionalists
Dialysis Pts
Increase sales
Decrease stenosis rates 50%
Ease pain & hassle
Licensing
Direct Sales
Publish: JAMA, Circulation, J Vasc
Surgery,
Conference: Kidney Week
Increase graft life 25%
Increase time to 1st
intervention 25%
![Page 26: Affinity I-Corps@NIH 121014](https://reader033.vdocuments.net/reader033/viewer/2022052700/55a202911a28ab3d268b46f7/html5/thumbnails/26.jpg)
Final Canvas KA-KR-KP
26
Preclinical studies
Large animal studies
CROs
Value Analysis Committee
Licensed IP
Medical Device Co’s
Nat’l Kidney Foundation
Center for Devices & Radiological Health
Admin Contractor @ CMS
KOL
Affinity’s IP
Advisory Board
License IP
Freedom to Operate
![Page 27: Affinity I-Corps@NIH 121014](https://reader033.vdocuments.net/reader033/viewer/2022052700/55a202911a28ab3d268b46f7/html5/thumbnails/27.jpg)
What’s next?• Freedom to Operate
• Continue vetting drug-eluting AV graft and wrap MVPs
• Talk with Gore re: interest (possibly Bard)
• Cultivate relationship with KOL Dr. Timmy Lee at UAB (Interview 116)
• Potential clinical and commercial relationship.
• Use Sales and Medical Science relations to build out KOL and Institutional relationships
• Harvard-associated hospitals
• Washington University/Barnes-Jewish
• University Hospital at Case Medical Center
27
![Page 28: Affinity I-Corps@NIH 121014](https://reader033.vdocuments.net/reader033/viewer/2022052700/55a202911a28ab3d268b46f7/html5/thumbnails/28.jpg)
Phase II SBIR Grant
• Affinity plans to submit a Phase II SBIR proposal after a minor pivot.
• This proposal will be submitted in 2016 because Affinity has a two year SHIFT award.
28
Investment Readiness Level
![Page 29: Affinity I-Corps@NIH 121014](https://reader033.vdocuments.net/reader033/viewer/2022052700/55a202911a28ab3d268b46f7/html5/thumbnails/29.jpg)
Final Slide – whew!
• Final Video on Youtube: http://youtu.be/SYWmiJgDnAs
29
Sean Zuckerman Horst von Recum Paul OlsonPI C Level Industry Expert